Ignite Creation Date:
2024-06-16 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06446388
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-06
First Post:
2024-06-01
Brief Title:
Study of QLS31905 andor QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors
Sponsor:
Qilu Pharmaceutical Co Ltd
Organization:
Qilu Pharmaceutical Co Ltd
Study Overview
Official Title:
A Phase II Clinical Study to Evaluate the Efficacy and Safety of QLS31905 andor QL1706 Combination Chemotherapy for the Treatment of CLDN182-Positive Advanced Malignant Solid Tumors
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to evaluate the efficacy and safety of QLS31905 andor QL1706 plus chemotherapy in patients with Claudin182-positive advanced solid tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None